Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Biological sex differences behind men's increased cancer risk
Tues August 9th - Underlying biological sex differences rather than behavioural differences could be why men are at greater risk of most cancers than women, according to a new analysis. More
Genetically profile all patients' cancers, say experts
Tues August 9th - The NHS should offer all cancer patients genetic profiling of their cancers to help inform their care and to track how the disease evolves, experts say today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Promising new immunotherapy results in early trial

Monday April 11th 2022

A new type of immunotherapy has shown early promise as an effective treatment for a range of solid tumours.

Results from a phase I trial show that AFM24 redirects the body’s own natural killer cells and engages them to kill tumour cells, without having to go through a complex process to re-engineer a patient’s own cells, which is what occurs in CAR-T cell therapy.

An international team, which included teams from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, UK, assessed the new treatment in 24 patients for safety and appropriate dosage, as well as its efficacy in solid tumours positive for EGFR.

They found it effective in one third who had advanced cancers that no longer responded to standard treatment.

It is believed the new treatment could also be safer and less complex than cell therapies such as CAR-T and might work against a wider range of cancer types.

Early findings have been presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Eight of the 24 participants responded to the immunotherapy and saw their cancer stop growing after being treated with AFM24 intravenously: two bowel cancer patients and one lung cancer patient who received the immunotherapy saw their cancer shrink or stop growing for more than three months.

The research team say the immunotherapy has a ‘warhead’ targeted at EGFR, which is commonly produced by lung, bowel, kidney, stomach, pancreatic and biliary cancers. It activates natural killer cells and directs them to cancer cells expressing EGFR which increases their ability to selectively kill cancer cells.

Dr Juanita Lopez, clinical researcher at The Institute of Cancer Research, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, the trial’s UK lead, said: “This treatment is still highly experimental and our trial is at an early stage, but we are excited by its potential. It does not have to be personalised for each patient like CAR-T cell therapy, so it could potentially be cheaper and faster to use and might work against a wider range of cancers.”

Professor Kristian Helin, chief executive of The Institute of Cancer Research, added: “We have seen major strides in the use of immunotherapy for cancer over recent years, with particular excitement over the use of ‘cell therapies’ to direct immune cells at tumours, often by engineering a patient’s own cells.

“This new treatment is highly innovative because it finds a way to direct natural killer cells within the immune system to tumours without requiring complex and expensive re-engineering of a patient’s own cells.”

The next phase of research will further evaluate the effectiveness of AFM24.

Tags: Cancer | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)